These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Enhancement of platelet recovery after myelosuppressive chemotherapy by recombinant human megakaryocyte growth and development factor in patients with advanced cancer. Basser RL, Underhill C, Davis I, Green MD, Cebon J, Zalcberg J, MacMillan J, Cohen B, Marty J, Fox RM, Begley CG. J Clin Oncol; 2000 Aug; 18(15):2852-61. PubMed ID: 10920133 [Abstract] [Full Text] [Related]
45. The prolonged hematologic effects of a single injection of PEG-rHuMGDF in normal and thrombocytopenic mice. Ulich TR, del Castillo J, Senaldi G, Cheung E, Roskos L, Young J, Molineux G, Guo J, Schoemperlen J, Munyakazi L, Murphy-Filkins R, Tarpley JE, Toombs CF, Kaufman S, Yin S, Nelson AG, Nichol JL, Sheridan WP. Exp Hematol; 1999 Jan; 27(1):117-30. PubMed ID: 9923450 [Abstract] [Full Text] [Related]
57. Marked improvement of thrombocytopenia in a murine model of idiopathic thrombocytopenic purpura by pegylated recombinant human megakaryocyte growth and development factor. Shibuya K, Kuwaki T, Tahara E, Yuki C, Akahori H, Kato T, Miyazaki H. Exp Hematol; 2002 Oct 01; 30(10):1185-92. PubMed ID: 12384150 [Abstract] [Full Text] [Related]